Best Cardiac and Vascular Disorders Companies in Switzerland
The 47 best Cardiac and Vascular Disorders companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Xeltis.
Ranked: Best Cardiac and Vascular Disorders companies in Switzerland
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Xeltis Developer of bioabsorbable synthetic heart valves and vascular grafts | $164M | 8 mo ago | 68 | Eliane Schutte Chief Executive Officer | WordPressMySQLPHP+20 | Top 10M | 68 patents Patents concentrated in health & consumer products | — |
| 2 | Cardiorentis Developer of natriuretic peptides for the treatment of cardiovascular diseases | $119M | 127 mo ago | 9 | Johannes Holzmeister CEO | — | — | 30 patents Patents concentrated in health & consumer products | — |
| 3 | Speedel Develops renin inhibitors for the treatment of cardiovascular and metabolic diseases | $100M | 234 mo ago | 40 | Andrin Oswald CEO | — | — | — | — |
| 4 | Occlutech Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart… | $81M | 55 mo ago | 290 | Tor Peters Founder & CEO | WordPressMySQLPHP+20 | Top 5M | 6 patents Patents concentrated in health & consumer products | — |
| 5 | Argá Medtech Developer of medical devices for treating cardiac arrhythmias | $59M | 29 mo ago | 8 | David Neale CEO and co-founder | GoDaddy Website BuilderApple iCloud MailMicrosoft 365+10 | Top 50M | — | — |
| 6 | Aktiia Developer of wearable blood pressure monitoring devices | $58M | 29 mo ago | 72 | Mattia Bertschi Founder & CEO | WordPressMySQLPHP+27 | Top 5M | 19 patents Cuffless blood pressure monitoring using high‑SNR photoplethysmography sensors | — |
| 7 | Symetis Heart valve replacement devices | $57M | 190 mo ago | 300 | — | — | — | 375 patents Transcatheter aortic valve replacement devices and their catheter delivery systems | — |
| 8 | Corflow Developer of diagnostic and therapeutic solutions for microvascular obstruction | $51M | 23 mo ago | 12 | Paul Mead CEO | WordPressMySQLPHP+19 | Top 50M | — | — |
| 9 | Spectrum Dynamics Manufacturer of cardiac imaging systems | $29M | — | 106 | — | WordPressMySQLPHP+20 | Top 10M | — | 1 expansion · 1 award |
| 10 | HAYA Therapeutics Developer of RNA-based therapies for treating heart diseases | $25M | 15 mo ago | 38 | Samir Ounzain Co-Founder & CEO | WordPressMySQLPHP+18 | Top 10M | 18 patents RNA therapeutics targeting lncRNAs, super-enhancers, and transposable elements for disease modulation | — |
| 11 | EBAMed Platform offering non-invasive treatments | $17M | 30 mo ago | 7 | — | — | — | 26 patents Patents concentrated in health & consumer products | — |
| 12 | Novostia Developer of artificial prosthetic heart valves | $16M | 22 mo ago | 10 | — | DrupalPHPGoogle Maps+15 | Top 50M | 18 patents Mechanical prosthetic heart valve devices for cardiac valve replacement | — |
| 13 | Hylomorph Developer of biomaterials with application in implantable medical devices | $14M | 35 mo ago | 13 | — | — | — | 11 patents Implantable controlled‑release drug delivery systems and insertion tools for insulin pump pouches | — |
| 14 | Berlin Heals Developer of a microcurrent device for heart failure treatment. | $12M | 6 mo ago | 19 19 → 38 (+100%) | Peter Goettel Co-Founder & Co-CEO | GSAPApache HTTP ServerCloudflare+5 | Top 50M | 20 patents Patents concentrated in health & consumer products | — |
| 15 | EP Solutions Non-invasive electrophysiology tools for cardiac mapping | $10M | 23 mo ago | 6 | Marcin Gołębicki Chief Executive Officer | — | — | — | — |
| 16 | Medyria Developer of technology for endovascular catheter navigation and sensing | $10M | 12 mo ago | 10 | — | — | — | 26 patents Intravascular catheter sensors for real-time blood flow velocity measurement | 1 expansion |
| 17 | Aeon Scientific Electromagnetic steering tech used for arrhythmia treatment | $8M | 143 mo ago | — | Dominik Bell CEO | — | — | — | — |
| 18 | 1Drop Diagnostics Provider of finger-prick point-of-care diagnostic solutions | $8M | 93 mo ago | 9 | — | Cart FunctionalityWooCommerceWordPress+20 | Top 50M | — | — |
| 19 | Inositec Developer of therapeutics for soft tissue calcification disorders | $1M | 117 mo ago | 6 | — | — | — | 8 patents Inhibiting renal calcium oxalate stone formation using inositol phosphate analogs | — |
| 20 | evismo Digital health diagnosis tool for healthcare providers | $1M | 58 mo ago | 9 | Willemien Van Den Toorn Founder & Co-CEO | BackdropOdooCart Functionality+14 | Top 10M | — | 1 job opening |
| 21 | SwissVortex Provider of cardiovascular technology development support and simulator platforms for medical device… | $494K | 67 mo ago | — | Andrea Guidotti Co-Founder | — | — | 21 patents Minimally invasive cardiovascular guidewire and suture fastening technologies | — |
| 22 | Orio Therapeutics Developer of regenerative drugs to treat myocardial infarction | $166K | 28 mo ago | — | Ziad Julier Co-Founder & CEO | — | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in Switzerland
#1
Series D · Zurich, Zurich · founded 2006 · 68 employees$164.4Mraised▾
Developer of bioabsorbable synthetic heart valves and vascular grafts. The implants function as natural valves and vessels, allowing the body to heal. As the matrix gets absorbed over time, components of native tissue develop into functioning natural tissue. The flagship product is a replacement pulmonary valve for children with congenital heart malformations.
- Dec 2025Venture Debt$43.6M
- Dec 2025Series D$11.6M
- Aug 2023Series D$13.7M
- Feb 2023Series D$34.2M
#2
Series B · Zug, Canton of Zug · founded 2010 · 19 employees$11.9Mraised▾
{}
- Feb 2026Series B$10M
- Sep 2025Series A$5M
- Feb 2025Series A$7.8M
- Jun 2023Series A$6.7M
#3
Series A · Lausanne, Vaud · founded 2017 · 38 employees$25Mraised▾
Developer of RNA-based therapies for treating heart diseases. It offers a platform that integrates multimodal functional genomics with computational tools to determine RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs) to inhibit lncRNAs to prevent Fibrosis.
- May 2025Series A$65M
- Feb 2022Seed$5M
- May 2021Seed$20M
- Nov 2017Grant (prize money)$40.3K
#4
Series B · Winterthur, Zurich · founded 2012 · 10 employees$10.4Mraised▾
Developer of technology for endovascular catheter navigation and sensing. Its products include Flowcath, TrackCath, and CPS for minimally invasive cardiovascular procedures, providing the physician with salient information about the catheter’s position in respect to the side branches.
- Jul 2025Series B$1.9M
- Jan 2023Series B$4M
- Feb 2018Series B$3.9M
- Jan 2015Series A$2.4M
#5
Series B · Baar, Zug · founded 2016 · 12 employees$51.3Mraised▾
Developer of diagnostic and therapeutic solutions for microvascular obstruction. It offers CoFI System that fits into the PCI workflow using the existing guide catheter and wire access for restoring healthy microvascular blood flow in the human body.
- Sep 2024Series B$48.6M
- Oct 2017Seed$2.6M
#6
Series A · Neuchatel, Neuchatel · founded 2017 · 10 employees$15.9Mraised▾
Developer of artificial prosthetic heart valves. The company is developing a heart valve that provides features such as an anatomic tri-leaflet design, biocompatible material, and anticoagulant-free. The device has completed preclinical testing. It can be used in aortic and mitral valve diseases.
- Sep 2024Series A$6.6M
- May 2023Series A$2.8M
- Mar 2023Grant (prize money)$54.4K
- Apr 2020Grant (prize money)$2.7M
#7
Series A · Geneva, Geneva · founded 2013 · 6 employees$10.4Mraised▾
EP Solutions develops non-invasive electrophysiology tools for cardiac mapping. Its proprietary technology enables simultaneous mapping of all four cardiac chambers, and on both epi-and endocardial surfaces. Applications involve pre and post-operative diagnosis of complex cardiac rhythm disturbances.
- Sep 2024Series A$4M
- Dec 2016Series A$10.4M
#8
Series B · Epalinges, Vaud · founded 2020 · 8 employees$58.5Mraised▾
Developer of medical devices for treating cardiac arrhythmias. The company is developing the next generation of Pulsed Field Ablation and Irreversible Electroporation devices for treating cardiac arrhythmias.
- Feb 2024Series B$58.5M
#9
Series B · Neuchatel, Neuchatel · founded 2018 · 72 employees$58.3Mraised▾
Developer of an optical blood pressure monitoring tool designed to prevent and assist in high blood pressure. The company's tool combines common optical sensors and clinically validated software algorithms to measure an individual's blood pressure at the wrist, enabling patients and healthcare professionals to understand the underlying causes of high blood pressure in order to develop new approaches to deal with the limiting and life-threatening condition.
#10
Series A · Geneva, Geneva · founded 2018 · 7 employees$17Mraised▾
Platform offering non-invasive treatments. It is a medical device company developing innovative solutions for non-invasive and automated treatment of heart arrhythmias. The company utilizes advanced technologies such as proton therapy to improve treatment outcomes. EBAMed's products aim to provide efficient and painless solutions for patients suffering from cardiac arrhythmias. The company has secured significant funding to advance its technology and expand its product offerings.
- Jan 2024Series A$1.7M
- Jun 2023Series A$15.6M
- Sep 2022Seed$101K
- Sep 2020Grant (prize money)$2.8M
#11
Series B · Zurich, Zurich · founded 2014 · 13 employees$14.2Mraised▾
Developer of biomaterials with application in implantable medical devices. The company is developing HYLOCARETM, an Anti-Fibrotic surgical pouch that prevents fibrosis. The films are easy to handle by the surgeons and ergonomically fit the target implant. The surgeons can mount them on the implants prior to surgery, without affecting the rest of the procedure.
- Sep 2023Series B$5.1M
- Sep 2023Grant (prize money)$2.7M
- Sep 2022Grant (prize money)$443.9K
- Apr 2022Grant (prize money)$52.7K
#12
Series C · Schaffhausen, Schaffhausen · founded 2003 · 290 employees$80.8Mraised▾
Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure. It provides ASD occluders, cardiac implants, and associated accessories to treat various structural heart defects like Atrial Septal Defect, Patent Foramen Ovale, Left Atrial Atresia, Patent Ductus Arteriosus, Paravalvular Leak, and others.
- Dec 2021Series C$49.2M
- Aug 2011Series B$21.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.